The ACER1 Knockout SK-OV-3 Polyclonal Cells product comprises a CRISPR/Cas9-mediated gene-disrupted polyclonal population of SK-OV-3 cells, providing a loss-of-function model for the ACER1 gene. Using a polyclonal editing strategy, the cell population is derived from the parental SK-OV-3 line following delivery of CRISPR/Cas9 reagents targeting the ACER1 locus, resulting in a mixed knockout architecture. This approach eliminates the need for single-cell cloning while enabling the study of gene disruption effects across a heterogeneous genetic background, making it suitable for pooled functional genomics and unbiased screening experiments. The absence of clonal selection ensures that results reflect a range of editing outcomes, reducing the risk of artifacts associated with monoclonal expansion.
The host SK-OV-3 cell line is a widely used human ovarian adenocarcinoma model, originally established from the ascitic fluid of a patient with progressive ovarian cancer. These cells exhibit an epithelial morphology and retain key characteristics of ovarian carcinoma, including aberrant proliferation and invasive potential. SK-OV-3 cells are aneuploid and express markers consistent with their tumor origin, such as mutant TP53 and amplified HER2. Their adherent growth and well-characterized signaling networks make them a standard platform for investigating oncogenic pathways, drug responses, and tumor microenvironment interactions in ovarian cancer research.
ACER1 encodes an alkaline ceramidase that hydrolyzes ceramide into sphingosine and a free fatty acid, a critical reaction at the nexus of sphingolipid metabolism and cell fate decisions. The enzyme is activated by cellular stress signals and pH alterations, functioning upstream of sphingosine and sphingosine-1-phosphate (S1P) generation. Sphingosine can be further phosphorylated by sphingosine kinases to produce S1P, a bioactive lipid that promotes cell proliferation, migration, and survival. By contrast, ceramide accumulation typically favors pro-apoptotic and anti-proliferative outcomes. Representative pathway components include ceramide synthases, sphingosine kinases, ceramide, sphingosine, and S1P, forming a tightly regulated metabolic node. In this polyclonal knockout population, ACER1 disruption abolishes alkaline ceramidase activity, leading to ceramide accumulation and reduced sphingosine and S1P, thereby shifting signaling balance toward ceramide-mediated effects.
In the context of SK-OV-3 ovarian cancer cells, ACER1 knockout provides a physiologically relevant system to dissect sphingolipid-driven mechanisms of oncogenesis and therapy resistance. Ovarian tumors often exhibit dysregulated sphingolipid metabolism, and modulation of ceramide?CS1P rheostat is implicated in apoptosis evasion and metastatic dissemination. This model enables dissection of how ceramide accumulation and S1P depletion influence SK-OV-3 behavior, including apoptotic susceptibility, proliferation kinetics, and migratory capacity. Because the polyclonal population preserves genomic heterogeneity, it recapitulates the cellular diversity encountered in tumor samples, enhancing translational relevance for studying drug targets within the sphingolipid pathway.
Investigators can employ this knockout model in diverse experimental workflows, including western blotting for ceramide levels, quantitative measurement of S1P, apoptosis assays using annexin V or caspase activation readouts, and cell proliferation studies via BrdU or MTT. Migration and invasion assays, such as transwell or scratch wound tests, can reveal phenotypic alterations in response to ACER1 loss. Drug sensitivity screens targeting sphingolipid metabolism??for example, using sphingosine kinase inhibitors or ceramide analogs??can identify synthetic lethal interactions or resistance mechanisms. Functional genomics applications, such as CRISPR modifier screens, may also leverage this polyclonal knockout to map genetic interactions within the sphingolipid network. For further information, contact Ascent Research.
